• About us
• Contact

Advertisement

Organisation › Details

BioNTech SE (Nasdaq: BNTX)

BioNTech SE is Europe’s largest privately-held biopharmaceutical company pioneering the development of precision immunotherapies for individualized treatment of cancer and prevention of infectious diseases. The company combines all building blocks for more precise and individualized immunotherapies under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based product candidates through innovative chimeric antigen receptors and T-cell receptor-based compounds to novel checkpoint immunomodulators and small molecules. BioNTech’s product development approach has been validated by seven corporate partnerships with, in chronological order, Genmab, Eli Lilly and Company, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant and Pfizer, and its scientific approach through over 60 peer-reviewed scientific publications. Founded in 2008, BioNTech’s financial shareholders include the Struengmann Family Office as its majority shareholder, Fidelity Management & Research Company, Invus, Janus Henderson Investors, MIG Fonds, Redmile Group, Salvia and several European family offices. *

 

	Start	2019-05-08 reorganised before
	Group	BioNTech (Group)
	Predecessor	BioNTech AG
	Industry	cancer immunotherapy (immuno-oncology, I-O)
	Industry 2	cancer test
	Person	Sahin, Ugur (BioNTech 201207 Managing Director BioNTech + Ribological GmbH)
	Person 2	Holstein, Jens (BioNTech 202107– CFO before MorphoSys 201105–202012 CFO before Fresenius Kabi)
	Region	Mainz
	Country	Germany
	Street	12 An der Goldgrube
	City	55131 Mainz
		Address record changed: 2024-03-22
Basic data	Employees	G: 5,001 to 10,000 (2023-12-31)
	Currency	EUR
	Annual sales	3,819,000,000 (revenues, total, consolidated (2023) 2023-12-31)
	Profit	930,300,000 (2023-12-31)
	Cash	11,663,700,000 (2023-03-31)
		* Document for »About Section«: BioNTech SE. (5/8/19). "Press Release: BioNTech Acquires MabVax Therapeutics’ Antibody Assets to Expand Portfolio". Mainz.
		Record changed: 2024-09-04

Advertisement

More documents for BioNTech (Group)

• [1] Tempus AI, Inc.. (9/4/24). "Press Release: Tempus Announces Real World Data Collaboration with BioNTech". Chicago....
• [2] BioNTech SE. (8/22/24). "Press Release: Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine". New York, NY & Mainz....
• [3] BioNTech SE. (8/19/24). "Press Release: Lift of Partial Clinical Hold for BNT326/YL202"....
• [4] BioNTech SE. (8/16/24). "Press Release: Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age". New York, NY & Mainz....
• [5] BioNTech SE. (8/5/24). "Press Release: BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update". Mainz....
• [6] Triastek, Inc.. (7/23/24). "Press Release: Triastek Announces Research Collaboration and Platform Technology License Agreement with BioNTech to Advance 3D Printed Oral RNA Therapeutics". Nanjing....
• [7] Haya Therapeutics SA. (7/1/24). "Press Release: Haya Therapeutics Co-Founders Win Inaugural Andreas & Thomas Struengmann Award". Lausanne & San Diego, CA....
• [8] BioNTech SE. (6/24/24). "Press Release: BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer". Mainz & Shanghai....
• [9] BioNTech SE. (5/29/24). "Press Release: BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem". Mainz & Oslo....
• [10] BioNTech SE. (5/22/24). "Press Release: BioNTech to Evaluate NanoTag’s Target Labeling System in Different Therapeutic Areas". Mainz & Göttingen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.